Patents by Inventor Claudio Pietra
Claudio Pietra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250235442Abstract: The invention concerns the use of compounds represented by formula (I) as inotropic agents. The compounds of formula (I), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.Type: ApplicationFiled: February 21, 2025Publication date: July 24, 2025Applicants: Helsinn Healthcare SA, Anacardio ABInventors: Lars Lund, Alberto Bernareggi, Emanuela Lovati, Claudio Giuliano, Claudio Pietra
-
Publication number: 20250205216Abstract: The invention concerns the use of compounds represented by formula (I) as inotropic agents. The compounds of formula (1), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.Type: ApplicationFiled: June 2, 2022Publication date: June 26, 2025Applicants: Helsinn Healthcare SA, Anacardio ABInventors: Lars Lund, Alberto Bernareggi, Emanuela Lovati, Claudio Giuliano, Claudio Pietra
-
Publication number: 20240293388Abstract: The new compound 3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea monohydrochloride salt has a high capability to permeate through the blood-brain barrier and to display, at central nervous system level, a consistent ghrelin agonist activity; the compound is effective in the treatment and/or prevention of a medical condition mediated by the ghrelin receptor in the central nervous system. In particular, in experimental tests, the compound has shown high efficacy in the treatment of neurotoxic damage, with a useful combined pattern of neuroprotective effects both at central and peripheral level. The compound is further useful in the treatment of conditions which require a reduction of the heart rate. The compound is pharmacologically active at low to moderate doses, thus showing a favourable therapeutic index.Type: ApplicationFiled: May 2, 2024Publication date: September 5, 2024Applicant: Helsinn Healthcare SAInventors: Claudio Giuliano, Claudio Pietra, Silvina Garcia Rubio, Angelo Guainazzi, Marielle Martinez-Loi
-
Patent number: 12071421Abstract: Disclosed are compounds including phosphate and N-oxide prodrugs of the NK1 antagonist netupitant, useful in the prevention and/or treatment of diseases including emesis induced by chemotherapy. Also disclosed are methods of making a di-tert-butyl (chloromethyl) phosphate useful in the manufacture of such prodrugs by reacting a dialkylphosphate salt with an acid to obtain the corresponding ester of phosphoric acid, reacting the ester with a quaternary ammonium hydroxide base to form a monobasic salt, and reacting the monobasic salt with chloroiodomethane to form the corresponding chloromethyl dialkyl phosphate.Type: GrantFiled: March 21, 2022Date of Patent: August 27, 2024Assignee: Helsinn Healthcare SAInventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stella
-
Publication number: 20240277688Abstract: The invention concerns the use of compounds represented by formula (I) as inotropic agents. The compounds of formula (I), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenypethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.Type: ApplicationFiled: June 2, 2022Publication date: August 22, 2024Applicants: Helsinn Healthcare SA, Anacardio ABInventors: Lars Lund, Alberto Bernareggi, Emanuela Lovati, Claudio Giuliano, Claudio Pietra
-
Patent number: 12005056Abstract: The new compound 3-(1-(2,3-dichloro-4-methoxyphenyl) ethyl)-1-methyl-1-(1,3, 3-trimethylpiperidin-4-yl)urea monohydrochloride salt has a high capability to permeate through the blood-brain barrier and to display, at central nervous system level, a consistent ghrelin agonist activity; the compound is effective in the treatment and/or prevention of a medical condition mediated by the ghrelin receptor in the central nervous system. In particular, in experimental tests, the compound has shown high efficacy in the treatment of neurotoxic damage, with a useful combined pattern of neuroprotective effects both at central and peripheral level. The compound is further useful in the treatment of conditions which require a reduction of the heart rate. The compound is pharmacologically active at low to moderate doses, thus showing a favourable therapeutic index.Type: GrantFiled: March 14, 2019Date of Patent: June 11, 2024Assignee: Helsinn Healthcare SAInventors: Claudio Giuliano, Claudio Pietra, Silvina Garcia Rubio, Angelo Guainazzi, Marielle Martinez-Loi
-
Patent number: 11976575Abstract: An organic Rankine cycle system with cascade cycles provided with a first organic Rankine cycle which operates at high temperature, in which a first organic working fluid carries out a heat exchange with a hot source fluid and a second organic Rankine cycle which operates at a temperature lower than the temperature of the first organic Rankine cycle and in which a second organic working fluid carries out a heat exchange with the same hot source. The evaporator of the first organic Rankine cycle is fed by the entire flow rate of the hot source fluid, while the evaporator and the preheater of the second organic Rankine cycle are fed by a first partial flow of the hot source fluid, the remaining second partial flow of the hot source fluid being used to partially carry out the preheating of the organic working fluid of the first organic Rankine cycle.Type: GrantFiled: May 26, 2021Date of Patent: May 7, 2024Assignee: TURBODEN S.P.A.Inventors: Mario Gaia, Roberto Bini, Claudio Pietra
-
Patent number: 11884646Abstract: Provided are various embodiments relating to fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, and methods of producing and using the same to treat conditions and disorders associated with an increase of ghrelin level, such as food abuse, alcohol addiction, and other disorders (e.g., Prader-Willi syndrome). Also provided are various embodiments relating to crystalline HM04 free base, different crystalline forms of HM04 fumarate salt, and methods of producing the same.Type: GrantFiled: March 7, 2022Date of Patent: January 30, 2024Assignee: HELSINN HEALTHCARE SAInventors: Silvina Garcia Rubio, Mauro Perseghini, Angelo Guainazzi, Claudio Pietra, Claudio Giuliano
-
Patent number: 11802494Abstract: A cascade organic Rankine cycle plant comprising a hot source, at least a first high temperature organic Rankine cycle and a second low temperature organic Rankine cycle, said cycles comprising at least one preheater, at least one vaporizer, at least one turbine, at least one condenser, wherein the hot source first supplies a vaporizer of the high temperature cycle, then the vaporizer of the low temperature cycle and finally it is divided into two flows which supply a first preheater of the high temperature cycle and a preheater of the low temperature cycle. The first high-temperature organic Rankine cycle comprises a further vaporizer operating at an intermediate pressure between the vaporizer pressure of the high temperature cycle and the vaporizer pressure of the low temperature cycle.Type: GrantFiled: April 30, 2020Date of Patent: October 31, 2023Assignee: TURBODEN S.p.A.Inventors: Roberto Bini, Mario Gaia, Claudio Pietra
-
Publication number: 20230220789Abstract: An organic Rankine cycle system with cascade cycles provided with a first organic Rankine cycle which operates at high temperature, in which a first organic working fluid carries out a heat exchange with a hot source fluid and a second organic Rankine cycle which operates at a temperature lower than the temperature of the first organic Rankine cycle and in which a second organic working fluid carries out a heat exchange with the same hot source. The evaporator of the first organic Rankine cycle is fed by the entire flow rate of the hot source fluid, while the evaporator and the preheater of the second organic Rankine cycle are fed by a first partial flow of the hot source fluid, the remaining second partial flow of the hot source fluid being used to partially carry out the preheating of the organic working fluid of the first organic Rankine cycle.Type: ApplicationFiled: May 26, 2021Publication date: July 13, 2023Applicant: TURBODEN S.P.A.Inventors: Mario GAIA, Roberto BlNl, Claudio Pietra
-
Publication number: 20230158007Abstract: The new compound 3-(1-(2,3-dichloro-4-methoxyphenyl) ethyl)-1-methyl-1-(1,3, 3-trimethylpiperidin-4-yl)urea monohydrochloride salt has a high capability to permeate through the blood-brain barrier and to display, at central nervous system level, a consistent ghrelin agonist activity; the compound is effective in the treatment and/or prevention of a medical condition mediated by the ghrelin receptor in the central nervous system. In particular, in experimental tests, the compound has shown high efficacy in the treatment of neurotoxic damage, with a useful combined pattern of neuroprotective effects both at central and peripheral level. The compound is further useful in the treatment of conditions which require a reduction of the heart rate. The compound is pharmacologically active at low to moderate doses, thus showing a favourable therapeutic index.Type: ApplicationFiled: March 14, 2019Publication date: May 25, 2023Applicant: Helsinn Healthcare SAInventors: Claudio Giuliano, Claudio Pietra, Silvina Garcia Rubio, Angelo Guainazzi, Marielle Martinez-Loi
-
Publication number: 20220401463Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.Type: ApplicationFiled: March 21, 2022Publication date: December 22, 2022Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stella
-
Publication number: 20220340541Abstract: Provided are various embodiments relating to fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, and methods of producing and using the same to treat conditions and disorders associated with an increase of ghrelin level, such as food abuse, alcohol addiction, and other disorders (e.g., Prader-Willi syndrome). Also provided are various embodiments relating to crystalline HM04 free base, different crystalline forms of HM04 fumarate salt, and methods of producing the same.Type: ApplicationFiled: March 7, 2022Publication date: October 27, 2022Applicant: Helsinn Healthcare SAInventors: Silvina Garcia Rubio, Mauro Perseghini, Angelo Guainazzi, Claudio Pietra, Claudio Giuliano
-
Publication number: 20220205370Abstract: A cascade organic Rankine cycle plant comprising a hot source, at least a first high temperature organic Rankine cycle and a second low temperature organic Rankine cycle, said cycles comprising at least one preheater, at least one vaporizer, at least one turbine, at least one condenser, wherein the hot source first supplies a vaporizer of the high temperature cycle, then the vaporizer of the low temperature cycle and finally it is divided into two flows which supply a first preheater of the high temperature cycle and a preheater of the low temperature cycle. The first high-temperature organic Rankine cycle comprises a further vaporizer operating at an intermediate pressure between the vaporizer pressure of the high temperature cycle and the vaporizer pressure of the low temperature cycle.Type: ApplicationFiled: April 30, 2020Publication date: June 30, 2022Applicant: TURBODEN S.P.A.Inventors: Roberto BlNl, Mario GAIA, Claudio PIETRA
-
Patent number: 11312698Abstract: Fosnetupitant chloride hydrochloride having improved stability, characterized by the following chemical structure:Type: GrantFiled: June 8, 2020Date of Patent: April 26, 2022Assignee: Helsinn Healthcare SAInventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stella
-
Patent number: 11299472Abstract: Provided are various embodiments relating to fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, and methods of producing and using the same to treat conditions and disorders associated with an increase of ghrelin level, such as food abuse, alcohol addiction, and other disorders (e.g., Prader-Willi syndrome). Also provided are various embodiments relating to crystalline HM04 free base, different crystalline forms of HM04 fumarate salt, and methods of producing the same.Type: GrantFiled: December 7, 2018Date of Patent: April 12, 2022Assignee: HELSINN HEALTHCARE SAInventors: Silvina Garcia Rubio, Mauro Perseghini, Angelo Guainazzi, Claudio Pietra, Claudio Giuliano
-
Publication number: 20200399240Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.Type: ApplicationFiled: June 8, 2020Publication date: December 24, 2020Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stella
-
Publication number: 20200299260Abstract: Provided are various embodiments relating to fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea, and methods of producing and using the same to treat conditions and disorders associated with an increase of ghrelin level, such as food abuse, alcohol addiction, and other disorders (e.g., Prader-Willi syndrome). Also provided are various embodiments relating to crystalline HM04 free base, different crystalline forms of HM04 fumarate salt, and methods of producing the same.Type: ApplicationFiled: December 7, 2018Publication date: September 24, 2020Applicant: Helsinn Healthcare SAInventors: Silvina GARCIA RUBIO, Mauro PERSEGHINI, Angelo GUAINAZZI, Claudio PIETRA, Claudio GIULIANO
-
Publication number: 20200262850Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula I: or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: January 24, 2020Publication date: August 20, 2020Inventors: Claudio Giuliano, Silvina Garcia Rubio, Antoine Daina, Angelo Guainazzi, Claudio Pietra
-
Patent number: 10717721Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.Type: GrantFiled: December 21, 2018Date of Patent: July 21, 2020Assignee: Helsinn Healthcare SAInventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stella